[go: up one dir, main page]

NO20061700L - 2-pyridonderivater som neutrofil elastase inhibitorer og deres anvendelse - Google Patents

2-pyridonderivater som neutrofil elastase inhibitorer og deres anvendelse

Info

Publication number
NO20061700L
NO20061700L NO20061700A NO20061700A NO20061700L NO 20061700 L NO20061700 L NO 20061700L NO 20061700 A NO20061700 A NO 20061700A NO 20061700 A NO20061700 A NO 20061700A NO 20061700 L NO20061700 L NO 20061700L
Authority
NO
Norway
Prior art keywords
neutrophil elastase
elastase inhibitors
pyridone derivatives
inhibitors
pyridone
Prior art date
Application number
NO20061700A
Other languages
English (en)
Inventor
Peter Hansen
Hans Lonn
Karolina Lawitz
Antonios Nikitidis
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29212489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061700(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20061700L publication Critical patent/NO20061700L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det er tilveiebragt nye forbindelser med formel (I) hvori R1, R2, R4, R5, G1, G2, L, Y og n er som definert i beskrivelsen og optiske isomerer, racemater og tautomerer derav, og farmasøytisk akseptable salter derav, sammen med en fremgangsmåte for deres fremstilling, sammensetninger som inneholder dem og deres anvendelse ved behandling. Forbindelsene er inhibitorer av neutrofil elastase.
NO20061700A 2003-09-18 2006-04-18 2-pyridonderivater som neutrofil elastase inhibitorer og deres anvendelse NO20061700L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302487A SE0302487D0 (sv) 2003-09-18 2003-09-18 Novel compounds
PCT/SE2004/001336 WO2005026124A1 (en) 2003-09-18 2004-09-15 2-pyridone derivatives as netrophil elastase inhibitors and their use

Publications (1)

Publication Number Publication Date
NO20061700L true NO20061700L (no) 2006-04-18

Family

ID=29212489

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061700A NO20061700L (no) 2003-09-18 2006-04-18 2-pyridonderivater som neutrofil elastase inhibitorer og deres anvendelse

Country Status (25)

Country Link
US (1) US20070043036A1 (no)
EP (1) EP1663974B1 (no)
JP (1) JP2007505902A (no)
KR (1) KR20060096995A (no)
CN (1) CN100439339C (no)
AR (1) AR046083A1 (no)
AT (1) ATE420861T1 (no)
AU (1) AU2004272485B2 (no)
BR (1) BRPI0414570A (no)
CA (1) CA2538410A1 (no)
CO (1) CO5670357A2 (no)
DE (1) DE602004019110D1 (no)
ES (1) ES2319300T3 (no)
IL (1) IL173986A0 (no)
IS (1) IS8394A (no)
MX (1) MXPA06002723A (no)
NO (1) NO20061700L (no)
RU (1) RU2348617C2 (no)
SA (1) SA04250300B1 (no)
SE (1) SE0302487D0 (no)
TW (1) TW200526579A (no)
UA (1) UA84878C2 (no)
UY (1) UY28513A1 (no)
WO (1) WO2005026124A1 (no)
ZA (1) ZA200602262B (no)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
US7728013B2 (en) * 2005-05-10 2010-06-01 Intermune, Inc. Method of modulating stress-activated protein kinase system
CA2618089A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
AU2006297036A1 (en) * 2005-09-29 2007-04-05 University Of Alberta Compositions for and methods of granzyme B inhibition
GB0605469D0 (en) * 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
US8470859B2 (en) 2006-10-23 2013-06-25 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
ES2424851T3 (es) 2006-11-08 2013-10-09 Bristol-Myers Squibb Company Compuestos de piridona
JP2011502982A (ja) 2007-11-06 2011-01-27 アストラゼネカ・アクチエボラーグ 好中球エラスターゼの阻害剤としてのある種の２−ピラジノン誘導体およびその使用
PL2327693T3 (pl) 2007-12-14 2012-11-30 Pulmagen Therapeutics Asthma Ltd Indole i ich zastosowanie terapeutyczne
ES2398335T3 (es) 2008-01-23 2013-03-15 Bristol-Myers Squibb Company Compuestos de 4-piridinona y su uso para el cáncer
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
ES2567283T3 (es) 2008-06-03 2016-04-21 Intermune, Inc. Compuestos y métodos para tratar trastornos inflamatorios y fibróticos
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
AU2010215261A1 (en) 2009-02-17 2011-09-08 Chiesi Farmaceutici S.P.A. Triazolopyridine derivatives as p38 MAP kinase inhibitors
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
EP2483244A1 (en) * 2009-10-02 2012-08-08 AstraZeneca AB 2-pyridone compounds used as inhibitors of neutrophil elastase
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
EP2509952A1 (en) * 2009-12-08 2012-10-17 Boehringer Ingelheim International GmbH Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
EP2740728A4 (en) 2011-08-01 2015-04-01 Sumitomo Dainippon Pharma Co Ltd URACIL DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
MY170656A (en) 2011-12-09 2019-08-24 Chiesi Farm Spa Kinase inhibitors
WO2013083606A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Kinase inhibitors
BR112014013178A2 (pt) 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
BR112015029970A2 (pt) 2013-06-06 2017-07-25 Chiesi Farm Spa inibidores de cinase
US9221807B2 (en) * 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
UY36875A (es) 2015-09-02 2017-03-31 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
EP3394058B1 (en) 2015-12-23 2020-10-14 Chiesi Farmaceutici S.p.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
AR107164A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa INHIBIDORES DE QUINASA p38
TW201730189A (zh) 2015-12-23 2017-09-01 吉斯藥品公司 激酶抑制劑
EP3452464B1 (en) 2016-05-05 2021-12-15 F. Hoffmann-La Roche AG Pyrazole derivatives, compositions and therapeutic use thereof
CA3035712A1 (en) 2016-09-06 2018-03-15 F. Hoffmann-La Roche Ag 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
CN110114343B (zh) 2016-12-29 2022-09-06 豪夫迈·罗氏有限公司 吡唑并嘧啶化合物及其使用方法
JP2020510061A (ja) 2017-03-14 2020-04-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピラゾロクロロフェニル化合物、組成物及びその使用方法
JP7256757B2 (ja) 2017-05-22 2023-04-12 エフ． ホフマン－ラ ロシュ アーゲー 処置用化合物及び組成物、並びにその使用方法
TW201900648A (zh) 2017-05-22 2019-01-01 瑞士商赫孚孟拉羅股份公司 治療性化合物及組成物以及其使用方法
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2019139714A1 (en) 2018-01-15 2019-07-18 Genentech, Inc. Pyrazolopyrimidine compounds as jak inhibitors
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
CN110192948B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿腹部热敷贴
CN110192947B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿肺部热敷贴
TW202115069A (zh) 2019-06-18 2021-04-16 瑞士商赫孚孟拉羅股份公司 Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途
EP3986899A1 (en) 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
BR112021025618A2 (pt) 2019-06-18 2022-02-01 Hoffmann La Roche Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto
EP4031138A1 (en) 2019-09-17 2022-07-27 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
AU2021256835A1 (en) 2020-04-16 2022-10-13 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
AU2022373971A1 (en) 2021-10-20 2024-04-04 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis
CN114057630B (zh) * 2021-12-23 2023-06-02 郑州大学 吡非尼酮衍生物及其合成方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
GB9207145D0 (en) * 1991-04-18 1992-05-13 Ici Plc Heterocyclic amides
FR2687674B1 (fr) * 1992-02-07 1995-05-19 Roussel Uclaf Nouveaux derives de la pyridone, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
DE69433705T2 (de) * 1993-11-19 2005-03-10 Parke, Davis & Company 5,6-Dihydropyronderivate als Proteaseinhibitoren und Antiviralmittel
RU2067579C1 (ru) * 1994-10-07 1996-10-10 Пермский фармацевтический институт 3-(2'-нафтоилметилен)-пиперазинон-2 и 1-n-фенил-3-фенацилиденпиперазинон-2, проявляющие противовоспалительную активность
CN100575345C (zh) * 2000-12-28 2009-12-30 盐野义制药株式会社 对2型大麻素受体具有结合活性的吡啶酮衍生物
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
GB2383326A (en) * 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines
ES2271365T3 (es) * 2001-12-20 2007-04-16 Bayer Healthcare Ag Derivados de 1,4-dihidro-1,4-difenilpiridina.
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
BRPI0414570A (pt) 2006-11-07
SE0302487D0 (sv) 2003-09-18
RU2006112427A (ru) 2007-11-10
UY28513A1 (es) 2005-04-29
ES2319300T3 (es) 2009-05-06
IS8394A (is) 2006-03-31
ATE420861T1 (de) 2009-01-15
CN1856467A (zh) 2006-11-01
HK1089167A1 (en) 2006-11-24
CO5670357A2 (es) 2006-08-31
AU2004272485A1 (en) 2005-03-24
AU2004272485B2 (en) 2008-03-13
CN100439339C (zh) 2008-12-03
RU2348617C2 (ru) 2009-03-10
UA84878C2 (ru) 2008-12-10
MXPA06002723A (es) 2006-06-06
WO2005026124A1 (en) 2005-03-24
DE602004019110D1 (de) 2009-03-05
SA04250300B1 (ar) 2008-09-07
US20070043036A1 (en) 2007-02-22
ZA200602262B (en) 2007-07-25
KR20060096995A (ko) 2006-09-13
AR046083A1 (es) 2005-11-23
EP1663974A1 (en) 2006-06-07
EP1663974B1 (en) 2009-01-14
IL173986A0 (en) 2006-07-05
CA2538410A1 (en) 2005-03-24
TW200526579A (en) 2005-08-16
JP2007505902A (ja) 2007-03-15

Similar Documents

Publication Publication Date Title
NO20061700L (no) 2-pyridonderivater som neutrofil elastase inhibitorer og deres anvendelse
NO20061660L (no) 2-pyridonderivate som neutrofil elasaeinhibitor og deres anvendelse
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
TW200500341A (en) Novel compounds
NO20084845L (no) 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig
NO20065456L (no) Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet
NO20054852L (no) GFAT inhibitorer
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20064400L (no) Prolin-derivater, og anvendelse av samme som inhibitorer av dipeptidyl peptidase IV
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
DE602004012758D1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
NO20073572L (no) Nye forbindelser
NO20081217L (no) Nye benzotiazolonderivater
NO20072399L (no) Nye pyrrolo[3,2-d]pyrimidin-4-o-derivater og deres anvendelse i terapi
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20051826L (no) Heterosyklisk substituerte piperaziner for behandling av schizofreni
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
SE0302323D0 (sv) Novel compounds
WO2007016392A3 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
NO20073571L (no) Nye hydantoinderivater som metallproteinaseinhibitorer
NO20070570L (no) Forbindelser.
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application